- Home
- / Morphic Therapeutic
Morphic Therapeutic
Stock Price
$57
2024-08-16
Market Capitalization
$2.9 B
2024-08-16
Revenue
$521 K
FY, 2023
Morphic Therapeutic Summary
Company Summary
- Overview
- Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Waltham, MA, US | view all locations
- Website
- http://morphictx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
William Devaul, General Counsel and Secretary
Joanne Gibbons, Senior Vice President, Regulatory and Quality
Hanh Nguyen, Senior Vice President, Technical Operations
LocationsView all
1 location detected
Waltham, MA HQ
United States
35 Gatehouse Dr
Morphic Therapeutic Financials
Summary Financials
- Net income (Q2, 2024)
- ($57.6M)
- Cash (Q2, 2024)
- $50.8M
- EBIT (Q2, 2024)
- ($65.2M)
- Enterprise value
- $2.8B